Related references
Note: Only part of the references are listed.Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review
Luca G. Campana et al.
RADIOLOGY AND ONCOLOGY (2016)
Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer
Gregor Sersa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Abscopal effect in the treatment of malignant melanoma
C. Thallinger et al.
HAUTARZT (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Matias E. Valsecchi
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
Nicola Mozzillo et al.
ONCOIMMUNOLOGY (2015)
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
James Larkin et al.
JAMA ONCOLOGY (2015)
Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation
Matteo Brizio et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2015)
Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy
Paola Queirolo et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2014)
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
Paola Queirolo et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
Antonio M. Grimaldi et al.
ONCOIMMUNOLOGY (2014)
Antitumor effectiveness of electrochemotherapy: A systematic review and meta-analysis
B. Mali et al.
EJSO (2013)
Utility of electrochemotherapy in melanoma treatment
Alessandro Testori et al.
CURRENT OPINION IN ONCOLOGY (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Electrochemotherapy -: An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases:: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study
Michel Marty et al.
EJC SUPPLEMENTS (2006)
Share Paper
